A new Taiwan biotech company will finish development of an HIV/AIDS drug from Genentech. The company hopes to have the drug on the market in a short three years. TaiMed Biologics was formed with the help of a $20 million infusion from the National Development Fund of Taiwan, an investment that gives the Fund a 40% stake in the company.
